Application of an Endothelial Cell Culture Assay for the Detection of Neutralizing Anti-Clostridium Perfringens Beta-Toxin Antibodies in a Porcine Vaccination Trial

CD31 (PECAM-1) Serves as the Endothelial Cell-Specific Receptor of Clostridium perfringens β-Toxin

Clostridium perfringens β-toxin (CPB) is a highly active β-pore-forming toxin (β-PFT) and the essential virulence factor for fatal, necro-hemorrhagic enteritis in animals and humans. The molecular mechanisms involved in CPB's action on its target, the endothelium of small intestinal vessels, are poorly understood. Here, we identify platelet endothelial cell adhesion molecule-1 (CD31 or PECAM-1) as the specific membrane receptor for CPB on endothelial cells. CD31 expression corresponds with the cell-type specificity of CPB, and it is essential for toxicity in cultured cells and mice. Ectopic CD31 expression renders resistant cells and liposomes susceptible to CPB-induced membrane damage. Moreover, the extracellular Ig6 domain of mouse, human, and porcine CD31 is essential for the interaction with CPB. Hence, our results explain the cell-type specificity of CPB in vitro and in the natural disease caused by C. perfringens type C.

Clostridium perfringens type C necrotic enteritis in pigs: diagnosis, pathogenesis, and prevention

Clostridium perfringens type C causes severe and lethal necrotic enteritis (NE) in newborn piglets. NE is diagnosed through a combination of pathology and bacteriologic investigations. The hallmark lesion of NE is deep, segmental mucosal necrosis with marked hemorrhage of the small intestine. C. perfringens can be isolated from intestinal samples in acute cases but it is more challenging to identify pathogenic strains in subacute-to-chronic cases. Toxinotyping or genotyping is required to differentiate C. perfringens type C from commensal type A strains. Recent research has extended our knowledge about the pathogenesis of the disease, although important aspects remain to be determined. The pathogenesis involves rapid overgrowth of C. perfringens type C in the small intestine, inhibition of beta-toxin (CPB) degradation by trypsin inhibitors in the colostrum of sows, and most likely initial damage to the small intestinal epithelial barrier. CPB itself acts primarily on vascular endothelial cells in the mucosa and can also inhibit platelet function. Prevention of the disease is achieved by immunization of pregnant sows with C. perfringens type C toxoid vaccines, combined with proper sanitation on farms. For the implementation of prevention strategies, it is important to differentiate between disease-free and pathogen-free status of a herd. The latter is more challenging to maintain, given that C. perfringens type C can persist for a long time in the environment and in the intestinal tract of adult animals and thus can be distributed via clinically and bacteriologically inapparent carrier animals.

Vaccination against Clostridium perfringens type C enteritis in pigs: a field study using an adapted vaccination scheme

Background

Clostridium perfringens type C induced necrotizing enteritis (NE) causes high mortality in newborn piglets. Immunization programs employing commercially available vaccines are used to prevent disease. Sows are vaccinated during every gestation period and piglets take up antibodies from the colostrum. Antibodies against the major clostridial toxin beta-toxin (CPB) are considered essential for protective immunity. Because the pathogen can persist for several years on farms, continuous vaccination is essential to protect pig herds from the re-occurrence of NE.

Results

In two field trials using commercially available vaccines we monitored neutralizing anti-CPB antibodies in pigs after vaccination. The first trial compared antibody titers in primiparous (gilts) and multiparous sows and their piglets after vaccination. A proportion of gilts and their piglets’ showed no or low antibody titers. All multiparous sows developed significantly higher serum and colostrum antibody titers after a booster vaccination shortly before their next farrowing. These colostral antibody titer highly correlated with the serum antibody titer of their piglets after consumption of colostrum. In a second field trial, we adapted the vaccination schemes using 3 instead of 2 initial vaccinations before the first farrowing of gilts. This significantly increased serum and colostrum antibody titers in gilts and serum antibody titers in piglets.

Conclusion

We demonstrate that despite following recommended vaccination protocols, a proportion of gilts might not sufficiently seroconvert to provide efficient passive immunity to their offsprings. A simple adaptation of the vaccination scheme can however improve passive protection of piglets from NE.